This phase 1–2, randomised, double-blind, placebo-controlled trial enrolled 130 patients aged 18 or older with confirmed ...

Both drugs are classified as guanylate cyclase-C agonists. Linzess capsules and Trulance tablets are available only as ...

Linaclotide, a guanylate cyclase C receptor agonist, has shown promising efficacy as a treatment for chronic constipation in a phase IIb, double-blinded, placebo-controlled, dose-ranging trial.

These cyclases represent a new guanylate cyclase subfamily, termed ROS-GC, which distinguishes itself from the peptide receptor guanylate cyclase family that it is not extracellularly regulated. It is ...

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

Pulmovant is tasked with taking forward mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, which is being developed to treat pulmonary hypertension associated with interstitial ...

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular smooth muscle and consequent ...

Its primary products include a portfolio of soluble guanylate cyclase (sGC) stimulators aimed at generating revenues and advancing its strategic initiatives. YTD Price Performance: 5.37% Average ...

Stephen, R., Palczewski, K., Sousa, M.C. (2008) Ca2+-dependent regulation of phototransduction. Photochem. And Photobiol. 84. 903-910 Stephen, R. (2008) Structural ...

a soluble guanylate cyclase activator and an off-the-shelf, virus-specific T cell therapy. These advances herald new hope for people with kidney disease. Progression of chronic kidney disease to ...